FDA Issues EUA for COVID-19 Monoclonal Antibody Treatment
November 23, 2020
When administered together in clinical trials, casirivimab and imdevimab were shown to lessen COVID-19 hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo.